Publications by authors named "Susanna Grassi"

Claim this Profile
Q
Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network.
Barbara Mantoan, Elisa Genuardi, Martina Ferrante, Irene Della Starza, Elena Ciabatti, Susanna Grassi

Hemasphere· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
Irene Della Starza, Lucia Anna De Novi, Marzia Cavalli, Noemi Novelli, Roberta Soscia, Susanna Grassi

Hematol Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation.
Federica Ricci, Serena Balducci, Francesca Guerrini, Susanna Grassi, Elena Ciabatti

Clin Hematol Int· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2.
Sara Galimberti, Mario Petrini, Claudia Baratè, Federica Ricci, Serena Balducci, Susanna Grassi

Front Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CoV-2 outbreak: how hematologists could help to fight Covid-19.
Sara Galimberti, Chiara Baldini, Claudia Baratè, Federica Ricci, Serena Balducci, Susanna Grassi

Pharmacol Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients.
Susanna Grassi, Francesca Guerrini, Elena Ciabatti, Riccardo Puccetti, Serena Salehzadeh

Cancers (Basel)· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.
Irene Della Starza, Marzia Cavalli, Lucia Anna De Novi, Elisa Genuardi, Barbara Mantoan, Susanna Grassi

Hematol Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice.
Sara Galimberti, Elisa Genuardi, Francesco Mazziotta, Lorenzo Iovino, Fortunato Morabito, Susanna Grassi

Front Oncol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia.
Susanna Grassi, Sara Palumbo, Veronica Mariotti, Diego Liberati, Francesca Guerrini

Front Oncol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients.
Serena Salehzadeh, Francesca Guerrini, Umberto Pizzano, Susanna Grassi, Elena Ciabatti

Cancer Cell Int· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia.
Sara Galimberti, Susanna Grassi, Claudia Baratè, Francesca Guerrini, Elena Ciabatti

Front Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup.
Elena Ciabatti, Angelo Valetto, Veronica Bertini, Maria Immacolata Ferreri, Alice Guazzelli, Susanna Grassi

Oncotarget· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The and polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.
Sara Galimberti, Cristina Bucelli, Elena Arrigoni, Claudia Baratè, Susanna Grassi

Oncotarget· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study.
Sara Galimberti, Elena Ciabatti, Giacomo Ercolano, Susanna Grassi, Francesca Guerrini

Front Pharmacol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.
Laura Galeotti, Francesco Ceccherini, Dario Domingo, Marco Laurino, Marialuisa Polillo, Susanna Grassi

Cancer Chemother Pharmacol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of V600E Mutation in Hairy Cell Leukemia.
Francesca Guerrini, Matteo Paolicchi, Francesco Ghio, Elena Ciabatti, Susanna Grassi

Front Pharmacol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.
Sara Galimberti, Stefano Luminari, Elena Ciabatti, Susanna Grassi, Francesca Guerrini

Clin Cancer Res· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.
Giovanni Carulli, Eugenio M Ciancia, Antonio Azzarà, Virginia Ottaviano, Susanna Grassi

J Clin Exp Hematop· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WT1 expression levels at diagnosis could predict long-term time-to-progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes.
Sara Galimberti, Francesco Ghio, Francesca Guerrini, Elena Ciabatti, Susanna Grassi

Br J Haematol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis